MeiraGTx Holdings plc reported cash, cash equivalents and restricted cash of $17.1 million as of September 30, 2025, compared to $105.7 million at December 31, 2024. Service revenue for the third quarter of 2025 was $0.4 million, down from $10.9 million in the same period in 2024, due to decreased activity of PPQ services under the asset purchase agreement with Johnson & Johnson Innovative Medicine. Cost of service revenue decreased to $0.3 million from $12.0 million in the prior year period. Interest income was $0.2 million, compared to $1.2 million, while interest expense was $3.1 million, down from $3.4 million. The company recorded a foreign currency loss of $1.6 million, compared to a gain of $3.5 million in the third quarter of 2024. During the quarter, MeiraGTx entered into a strategic collaboration with Eli Lilly for its AAV-AIPL1 program for Leber congenital amaurosis 4 and released material under its Specials license for a rare pediatric ophthalmology condition related to BBS10 mutations. The company expects sufficient capital to fund operations into the second half of 2027, including repayment of its $75.0 million debt due in August 2026, supported by recent and anticipated cash inflows from collaborations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575000-en) on November 13, 2025, and is solely responsible for the information contained therein.
Comments